A detailed history of Wells Fargo & Company transactions in Kempharm, Inc stock. As of the latest transaction made, Wells Fargo & Company holds 27,381 shares of KMPH stock, worth $135,262. This represents 0.0% of its overall portfolio holdings.

Number of Shares
27,381
Previous 23,908 14.53%
Holding current value
$135,262
Previous $118,000 14.41%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
N/A
3,473 Added 14.53%
27,381 $135,000
Q1 2024

May 10, 2024

BUY
N/A
149 Added 0.63%
23,908 $118,000
Q4 2023

Feb 09, 2024

BUY
N/A
2,788 Added 13.29%
23,759 $117,000
Q3 2023

Nov 13, 2023

BUY
N/A
2,921 Added 16.18%
20,971 $103,000
Q2 2023

Aug 15, 2023

BUY
$4.94 - $6.29 $64,086 - $81,600
12,973 Added 255.52%
18,050 $89,000
Q1 2023

May 12, 2023

BUY
$4.13 - $6.27 $12 - $18
3 Added 0.06%
5,077 $27,000
Q4 2022

Feb 13, 2023

SELL
$4.12 - $5.62 $313 - $427
-76 Reduced 1.48%
5,074 $23,000
Q3 2022

Nov 14, 2022

SELL
$4.5 - $6.85 $4,666 - $7,103
-1,037 Reduced 16.76%
5,150 $32,000
Q2 2022

Aug 12, 2022

SELL
$4.02 - $5.21 $11,814 - $15,312
-2,939 Reduced 32.2%
6,187 $27,000
Q1 2022

May 16, 2022

SELL
$5.0 - $9.26 $52,030 - $96,359
-10,406 Reduced 53.28%
9,126 $47,000
Q4 2021

Feb 14, 2022

SELL
$7.6 - $10.26 $150,016 - $202,522
-19,739 Reduced 50.26%
19,532 $171,000
Q3 2021

Nov 15, 2021

BUY
$8.72 - $13.31 $292,573 - $446,577
33,552 Added 586.68%
39,271 $366,000
Q2 2021

Aug 16, 2021

BUY
$8.52 - $15.47 $20,396 - $37,035
2,394 Added 72.0%
5,719 $73,000
Q1 2021

May 13, 2021

BUY
$5.6 - $13.47 $18,620 - $44,787
3,325 New
3,325 $30,000

Others Institutions Holding KMPH

About KEMPHARM, INC


  • Ticker KMPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 34,493,600
  • Market Cap $170M
  • Description
  • KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds t...
More about KMPH
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.